Cancers is the leading cause of morbidity and mortality worldwide, with approximately 14 million new cases and 8.2 million cancer related deaths in 2012[@b1]. The number of new cases is expected to rise by about 70% over the next 2 decades[@b2]. Searching and developing effective anticancer drugs is more and more important. Peptides and their derivatives are important molecules with versatile pharmacological properties[@b3], and which are normally designed to mimic a natural protein or peptide. Nevertheless, stability and bioavailability of peptides and mimetics can be improved by several modifications[@b4]. In addition, some dipeptide derivatives have exhibited potent inhibition activities against human tumors cells[@b5].

Besides that, steroids are a class of typical lipids found in living world that have broad biological activities[@b6], and which have been widely used in medicine as essentials of anti-inflammatory, anabolic, anticancer and contraceptive drugs[@b7]. Recent years, the modifications of natural steroid have become a focus of research probably on account of the various advantages associated with steroid based chemotherapeutics. Dehydroepiandrosterone (DHEA) is a major steroid secreted by the adrenal gland and the most abundant steroid in humans[@b8]. Furthermore, several steroidal derivatives have been investigated as potential anti-cancer agents for the treatment of breast cancer, prostate cancer, ovary cancer, lung cancer, gastric cancer, esophageal cancer, heptoma cancer, melanoma cancer, multiple myeloma[@b9][@b10][@b11][@b12][@b13][@b14][@b15][@b16][@b17][@b18]. On the other hand, structural modifications carried out at positions 17 of DHEA have exhibited a broad range biological activities as potent antimicrobial agents and anticancer agents[@b10][@b19].

Recently, during the course of our research for high active compounds, three series of novel peptidomimetics bearing natural tryptamine moiety were designed, synthesized, and evaluated for their inhibition activities against cell proliferation[@b20]. Some of the prepared compounds exhibited significant inhibition activities against human hepatoma cancer (HepG2 and Huh-7), human melanoma (A875) cell lines compared with the control 5-fluorouracil. The results from these investigations inspired us to further investigate the novel amino acid-conjugates of dehydroepiandrosterone, which adopt the natural DHEA scaffold to replace the natural tryptamine moiety ([Fig. 1](#f1){ref-type="fig"}). To study the possible structure-activity relationships, several efforts in structure modifications of such type of compounds were designed, and the synthesis of target compounds is simple and convenient as shown in [Fig. 2](#f2){ref-type="fig"}. Besides, their inhibition activities against various cancer cell lines (HepG2, A549, and A875) were also evaluated by MTT method, and the possible mechanism of action for the highly potential compounds were also evaluated using Annexin V-FITC/propidium iodide dual staining assay.

Results and Discussion
======================

Chemistry
---------

In the present study, a series of peptidomimetics including steroids groups were designed and synthesized in a simple and convenient route. The general synthetic method for all compounds is outlined in [Fig. 2](#f2){ref-type="fig"}.

The easily available amino acids **1a-g** was selected as staring materials, and which were transferred to the corresponding *N*-(tert-butoxycarbonyl)-amino acids and *N*-benzyloxycarbonyl-amino acids **2a-m** by electrophilic substitution reactions. Meanwhile, compounds dehydroepiandrosterone-17 hydrazone **4** and dehydroepiandrosterone-17 oxime **5** were conveniently prepared from dehydroepiandrosterone **3** by nucleophilic addition elimination reactions. Then the desired peptidomimetics **Ia-m** were obtained from N-protected amino acids **2a-m** and dehydroepiandrosterone-17 hydrazone **4** by nucleophilic substitution. Similarly, compounds **IIa-l** were also obtained from N-protected amino acids **2a-m** with dehydroepiandrosterone-17 oxime **5** by nucleophilic substitution as well. All the compounds gave satisfactory chemical analyses, and the chemical structures and physiochemical properties of the synthesized compounds were summarized in [Table 1](#t1){ref-type="table"}.

Although the condensation reactions between carboxylic acid and RNH~2~/ROH can be generated by a lot of catalysts, we wish to develop convenient and effective methods for our own syntheses. First, compound dehydroepiandrosterone-17 hydrazone **4** and N-cbz-L-valine was chosen as a model system ([Fig. 3](#f3){ref-type="fig"}). Six kinds of common and appropriate catalyst composition were examined and screened, dicyclohexylcarbodiimide and 4-dimethylaminopyridine (DCC/DMAP), dicyclohexylcarbodiimide and 4-methylmorpholine (DCC/NMM), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and 4-dimethylaminopyridine (EDCI/DMAP), O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate and triethylamine (TBTU/Et~3~N), trimethyl borate (B(OCH~3~)~3~), N,N'-carbonyldiimidazole and triethylamine (CDI/Et~3~N) ([Fig. 3](#f3){ref-type="fig"}, Entries **1--6**). CDI and Et~3~N composition was found to give the best conversion. Besides, we found high temperature cannot improve the conversion ([Fig. 3](#f3){ref-type="fig"}, Entries **6, 7**). Different solvents were screened in order to increase the conversion ([Fig. 3](#f3){ref-type="fig"}, Entries **6, 8, 9**). Acetonitrile was found to give the best conversion among the three solvents. Without triethylamine, the conversion has a little decrease ([Fig. 3](#f3){ref-type="fig"}, Entry **10**). Furthermore, different molar ratios for the substrates were also examined to increase the conversion ([Fig. 3](#f3){ref-type="fig"}, Entries **6, 11, 12**, and **13**). The best condition was shown in [Fig. 3](#f3){ref-type="fig"} as entry 6 in summary.

Inhibitory effects of compounds on the proliferation of various cancer cells
----------------------------------------------------------------------------

The newly prepared peptidomimetics derivatives were evaluated for their *in vitro* cytotoxic effects against HepG2 (hepatocellular liver carcinoma), A549 (Human lung cell line), A875 (human melanoma cell line) by the standard MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay[@b21] using 5-FU (5-Fluorouracil) as a positive control. The preliminary results were summarized in [Fig. 4](#f4){ref-type="fig"} and [Table 2](#t2){ref-type="table"}. The IC~50~ value represents the drug concentration required to inhibit cell growth by 50%.

Generally, as shown in [Fig. 4](#f4){ref-type="fig"}, the prepared peptidomimetics derivatives (1--26) showed moderate to good inhibition activities against the three tested human cancer cell lines. Most compounds displayed better inhibition activities than 5-FU. Notably, the compounds **Ia**, **Ib**, **Ii**, **Ij**, **Ik, Il**, and **IId**, **IIk**, **IIl** exhibited significant inhibitory activities against all three tested cell lines with 70.1--86.4% growth inhibition at 40 μg/mL concentration compared to the positive control 5-FU (56.6--65.3%). Also, it is interesting to note that compound **IIe** showed selective cytotoxicity to A549 cell line and A875 cell line with 62.1% and 62% growth inhibition respectively, and with 31% inhibitions to HepG2 cell lines.

Moreover, the preliminary bioassay indicated that most of the target compounds (such as **Ia**, **Ib**, **Ii**, **Ij**, **Ik**, and **IId**, **IIk** and **IIl**) displayed good inhibitory activities compared to 5-FU, so in order to investigate the potential activities, the IC~50~ values were further evaluated. The inhibitory activities expressed as IC~50~ values for the target compounds are presented in [Table 2](#t2){ref-type="table"}. The results also testify that some of the designed peptidomimetics derivatives exhibited higher inhibition activity than the control 5-FU under the same conditions. As indicated in [Table 2](#t2){ref-type="table"}, compound **IId** showed the strongest inhibitory effect against HepG2, with an IC~50~ value of 7 μM; compound **Ik** showed the strongest inhibitory effect against A549 and A875 with an IC~50~ value of 6 and 13 μM, respectively. We also can find that compound **Ib** have the same inhibition activities trend as 5-FU against the three cancer cell lines. Especially, compounds **Ib, Ic, Ii**, **Ik, Il, Im, IId** and **IIk** exhibited significant inhibition against all tested cancer cell lines compared to the positive control 5-FU.

Furthermore, the dose-response analysis of cell growth inhibition activity for representative compounds **Ii**, **Ik**, **IId** and 5-FU has been displayed in [Fig. 5](#f5){ref-type="fig"}, which revealed that the cytotoxic effects on cell lines of target compounds indicated obvious concentration-dependent manner.

Results of Annexin V-FITC assay for apoptosis
---------------------------------------------

Potential of the investigated compound **Ik** to induce apoptosis in HepG2 cells was analyzed by flow cytometry, following treatment with IC~50~ or 2 × IC~50~ concentrations for 24 h. The apoptotic effect of compound **Ik** was evaluated using Annexin V-FITC/PI dual staining assay, which can examine the occurrence of phosphatidylserine (PS) externalization as well as understand whether it is due to physiological apoptosis or nonspecific necrosis[@b22]. All data obtained in this study are presented in [Figs 6](#f6){ref-type="fig"} and [7](#f7){ref-type="fig"}, as a percentages of an early apoptotic cells, FITC(+)PI(−); late apoptotic cells, FITC(+)/PI(+); and necrotic cells, FITC(−)/PI(+); presenting intact cells, FITC(−)/PI(−).

Results revealed that compound **Ik** induced apoptotic changes following 24 h treatment. As shown in [Figs 6](#f6){ref-type="fig"} and [7](#f7){ref-type="fig"}, compound **Ik** initiated excellent apoptosis, in terms of FITC(+)PI(−) staining, compared to the control. Compound **Ik** exhibited 17.2% of apoptosis at IC~50~ and 51.5% of apoptosis at 2 × IC~50~ concentrations, whereas 2.5% of apoptosis was observed in control (0.1% DMSO). Besides, Compound **Ik** existed 75.7% of presenting intact cells at IC~50~ and 47.7% of presenting intact cells 2 × IC~50~ concentrations, while 95.6% of presenting intact cells was observed in control. From this experiment it was observed that the highly potential compound induced cell death in HepG2 cells at least partly (initially), by apoptosis. However, the precise mechanisms of cell death induction by tested compound still remain to be further explored.

Structure and activity relationship (SAR)
-----------------------------------------

Within the limits of experimental error, for the present series of compounds **Ia-f** and **IIa-f**, of which the N-protected group is carbobenzoxy, the compounds **Ia**, **Ib**, **Id**, **IIa**, **IIb** and **IId** displayed better antiproliferation activities. In terms of these compounds, the compounds with lower molecular weight indicated better inhibitory activities against the cell lines. On the contrary, when the N-protected group is tert-butoxycarbonyl, the other compounds **Il**, **Im**, **IIk** and **IIl** showed better inhibitory activities. It can be speculated, when steric hindrance is smaller, compounds bearing aromatic ring displayed better antiproliferation activities, otherwhise, compounds with lower molecular weight displayed better antitumor activities. As far as glycine and proline derivatives are concerned, N-carbobenzoxy protected target compounds displayed better inhibitory activities compared to N-*tert*-butoxycarbonyl-protected compounds. However, for phenylalanine and tryptophan derivatives, N-*tert*-butoxycarbonyl-protected compounds indicated better inhibitory activities. Meanwhile, we also can found that the compounds containing oxime unit presented poor antiproliferation activities than that of the compounds bearing hydrazine moiety, which perhaps to prove the importance of amide bond.

Conclusion
==========

In the present study, twenty-five novel peptidomimetics derivatives containing natural steroid moiety have been conveniently synthesized, and their potential antitumor activities have also been evaluated *in vitro*. The preliminary bioassay results indicated that some of the compounds displayed obviously good inhibition activities against human cancer cell lines including HepG2, A549 and A875, especially, compounds **Ii** and **Ik** exhibited high cytotoxic activities against the three cancer cell lines, which might be developed as novel lead scaffold for potential antitumor agents. The further annexin V-FITC assay revealed these highly potential compounds induced cell death in HepG2 cells at least partly by apoptosis.

Experimental
============

Synthesis of target compounds
-----------------------------

The instrumentation, chemicals, synthetic procedures and characterization were provided in [supplementary data](#S1){ref-type="supplementary-material"}.

*In vitro* cytotoxicity assays
------------------------------

The *in vitro* cytotoxicity of the synthesized compounds against different human cancer cell lines (HepG2, A549, A875) was measured with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay[@b21]. All the data of the experiment were analyzed with SPSS software, and the 50% inhibitory concentrations (IC~50~) of each compound for the different cell lines were determined. A control was run for each test, and all assays were performed in triplicate on three independent experiments, and measurement data were expressed as the mean ± S.D.

Flow cytometric analysis of apoptosis
-------------------------------------

Quantitative analysis of apoptotic and necrotic cell death induced by the test compounds was performed by Annexin V-FITC apoptosis detection kit according to the manufacturer's instructions (BD Biosciences). Briefly, 2 × 10^5^ HepG-2 cells were seeded in 6-well plates and grown overnight. After removal of the growth medium, cells were treated with compound **Ik** for 24 h, at concentrations corresponding to their IC~50s~ or 2 × IC~50s~. Cells treated with 0.1% DMSO were served as solvent control. Following treatment cells were harvested, washed twice with ice-cold PBS and resuspended in binding buffer. Then the cells were stained by adding 5 μL of Annexin V-FITC and 5 μL of propidium iodide, sit for 15 min at room temperature in the dark and analyzed by flow cytometry (Beckman coulter FC500).
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![Design strategy of novel amino acid-conjugates of dehydroepiandrosterone.](srep32654-f1){#f1}

![Synthetic route and conditions for target compounds.\
(1) (Boc)~2~O or CbzCl, NaOH, 0 ^o^C to rt, yields 65--80%; (2) NH~2~NH~2~·H~2~O, EtOH (X = NH) or NH~2~OH·HCl, CH~3~COONa, EtOH (X = O), reflux, yields 80--85%; (3) CDI, Et~3~N, MeCN, rt, yields 50--80%.](srep32654-f2){#f2}

![Reaction conditions screening.](srep32654-f3){#f3}

![Inhibition activities against cell proliferation for target compounds at 40 μg/mL.\
Abbreviations: HepG2 - Human hepatocellular liver carcinoma cell line; A549 -Human lung cell line; A875 - Human melanoma cell line; 5-FU - 5-Fluorouracil, used as a positive control.](srep32654-f4){#f4}

![Dose--response analysis of cell growth inhibitory activity for representative compounds **Ii**, **Ik**, **IId** and 5-FU (positive control) against HepG2 (left), A549 (middle) and A875(right) cell lines.](srep32654-f5){#f5}

![Annexin V-FITC flow cytometry.\
Cell cycle progression (**A**--**C**) and annexin V-FITC/PI staining was monitored in HepG2 cells following 24 h treatment with compound **Ik** at concentrations corresponding to their IC~50~ or 2 × IC~50~ (E and F). Representative dot plots of three independent experiments are given, presenting intact cells at lower-left quadrant, FITC(−)/PI(−); early apoptotic cells at lower-right quadrant, FITC(+)PI(−); late apoptotic or necrotic cells at upper-right quadrant, FITC(+)/PI(+); necrotic cells at upper-left quadrant, FITC(−)/PI(+).](srep32654-f6){#f6}

![Apoptotic effect of compound.\
**Ik** was evaluated after 24 h treatment; bar graphs represent mean ± SD in at least three independent experiments.](srep32654-f7){#f7}

###### Chemical structure of synthesized peptidomimetics derivatives.

![](srep32654-t1)

###### Cytotoxic activity of the compounds against different human liver cells.

  Entry    Compd. No.   *In vitro* cytotoxicity IC~50~[a](#t2-fn1){ref-type="fn"} (μM)             
  ------- ------------ ---------------------------------------------------------------- ---------- ----------
  1            Ia                     20 ± 4[c](#t2-fn3){ref-type="fn"}                   20 ± 3     18 ± 2
  2            Ib                                   15 ± 4                                17 ± 2     16 ± 6
  3            Ic                                   14 ± 4                                14 ± 3     14 ± 5
  4            Id                                   12 ± 5                                16 ± 3     19 ± 4
  5            Ie                                   19 ± 4                                22 ± 4     30 ± 8
  6            If                                    \>60                                  \>60       \>60
  7            Ig                                   35 ± 5                                32 ± 7     37 ± 1
  8            Ih                                   26 ± 7                                24 ± 6     27 ± 3
  9            Ii                                   9 ± 3                                 10 ± 3     14 ± 3
  10           Ij                                   24 ± 5                                21 ± 2     24 ± 2
  11           Ik                                   9 ± 2                                 6 ± 1      13 ± 1
  12           Il                                   11 ± 4                                8 ± 3      15 ± 6
  13           Im                                   10 ± 2                                10 ± 4     16 ± 5
  14          IIa                                   21 ± 1                                27 ± 6     29 ± 4
  15          IIb                                   24 ± 7                                19 ± 6     24 ± 0
  16          IIc                                   29 ± 4                                21 ± 5     17 ± 2
  17          IId                                   7 ± 3                                 13 ± 4     15 ± 4
  18          IIe                                    \>60                                 37 ± 5     40 ± 2
  19          IIf                                   28 ± 1                                21 ± 4     29 ± 9
  20          IIg                                   31 ± 6                                23 ± 4     20 ± 2
  21          IIh                                   23 ± 4                                18 ± 2     14 ± 1
  22          IIi                                   23 ± 7                                23 ± 2     22 ± 5
  23          IIj                                   22 ± 2                                20 ± 2     18 ± 1
  24          IIk                                   16 ± 2                                16 ± 3     18 ± 2
  25          IIl                                   17 ± 3                                15 ± 2     15 ± 2
  26       5-FU^*d*^                               84 ± 25                               115 ± 10   100 ± 24

^a^IC~50~ -- Compound concentration required to inhibit tumor cell proliferation by 50%.

^b^Abbreviations: HepG2 -- Human hepatocellular liver carcinoma cell line; A549 -- Human lung cell line; A875 -- human melanoma cell line.

^c^All assays were performed in triplicate on three independent experiments, and measurement data were expressed as the mean ± S.D.
